Michael R. Hayden - Publications

Affiliations: 
University of British Columbia, Vancouver, Vancouver, BC, Canada 
Area:
Biostatistics Biology

305 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Ehrnhoefer DE, Skotte NH, Reinshagen J, Qiu X, Windshügel B, Jaishankar P, Ladha S, Petina O, Khankischpur M, Nguyen YTN, Caron NS, Razeto A, Meyer Zu Rheda M, Deng Y, Huynh KT, ... ... Hayden MR, et al. Activation of Caspase-6 Is Promoted by a Mutant Huntingtin Fragment and Blocked by an Allosteric Inhibitor Compound. Cell Chemical Biology. PMID 31353319 DOI: 10.1016/j.chembiol.2019.07.001  1
2019 Smith-Dijak AI, Nassrallah WB, Zhang LYJ, Geva M, Hayden MR, Raymond LA. Impairment and Restoration of Homeostatic Plasticity in Cultured Cortical Neurons From a Mouse Model of Huntington Disease. Frontiers in Cellular Neuroscience. 13: 209. PMID 31156395 DOI: 10.3389/fncel.2019.00209  1
2019 Ferrari Bardile C, Garcia-Miralles M, Caron NS, Rayan NA, Langley SR, Harmston N, Rondelli AM, Teo RTY, Waltl S, Anderson LM, Bae HG, Jung S, Williams A, Prabhakar S, Petretto E, ... Hayden MR, et al. Intrinsic mutant HTT-mediated defects in oligodendroglia cause myelination deficits and behavioral abnormalities in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. PMID 31015293 DOI: 10.1073/pnas.1818042116  1
2019 Kang R, Wang L, Sanders SS, Zuo K, Hayden MR, Raymond LA. Altered Regulation of Striatal Neuronal -Methyl-D-Aspartate Receptor Trafficking by Palmitoylation in Huntington Disease Mouse Model. Frontiers in Synaptic Neuroscience. 11: 3. PMID 30846936 DOI: 10.3389/fnsyn.2019.00003  1
2018 Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Movement Disorders : Official Journal of the Movement Disorder Society. PMID 30575996 DOI: 10.1002/mds.27565  1
2018 Garcia-Miralles M, Yusof NABM, Tan JY, Radulescu CI, Sidik H, Tan LJ, Belinson H, Zach N, Hayden MR, Pouladi MA. Laquinimod Treatment Improves Myelination Deficits at the Transcriptional and Ultrastructural Levels in the YAC128 Mouse Model of Huntington Disease. Molecular Neurobiology. PMID 30334188 DOI: 10.1007/s12035-018-1393-1  1
2018 Southwell AL, Kordasiewicz HB, Langbehn D, Skotte NH, Parsons MP, Villanueva EB, Caron NS, Østergaard ME, Anderson LM, Xie Y, Cengio LD, Findlay-Black H, Doty CN, Fitsimmons B, Swayze EE, ... ... Hayden MR, et al. Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease. Science Translational Medicine. 10. PMID 30282695 DOI: 10.1126/scitranslmed.aar3959  1
2018 Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nature Reviews. Drug Discovery. PMID 30237454 DOI: 10.1038/nrd.2018.133  1
2018 Schmidt ME, Buren C, Mackay JP, Cheung D, Dal Cengio L, Raymond LA, Hayden MR. Altering cortical input unmasks synaptic phenotypes in the YAC128 cortico-striatal co-culture model of Huntington disease. Bmc Biology. 16: 58. PMID 29945611 DOI: 10.1186/s12915-018-0526-3  1
2018 Kusko R, Dreymann J, Ross J, Cha Y, Escalante-Chong R, Garcia-Miralles M, Tan LJ, Burczynski ME, Zeskind B, Laifenfeld D, Pouladi M, Geva M, Grossman I, Hayden MR. Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. Molecular Neurodegeneration. 13: 25. PMID 29783994 DOI: 10.1186/s13024-018-0259-3  1
2018 Ladha S, Qiu X, Casal L, Caron NS, Ehrnhoefer DE, Hayden MR. Constitutive ablation of caspase-6 reduces the inflammatory response and behavioural changes caused by peripheral pro-inflammatory stimuli. Cell Death Discovery. 4: 40. PMID 29560279 DOI: 10.1038/s41420-018-0043-8  1
2018 Ehrnhoefer DE, Martin DDO, Schmidt ME, Qiu X, Ladha S, Caron NS, Skotte NH, Nguyen YTN, Vaid K, Southwell AL, Engemann S, Franciosi S, Hayden MR. Preventing mutant huntingtin proteolysis and intermittent fasting promote autophagy in models of Huntington disease. Acta Neuropathologica Communications. 6: 16. PMID 29510748 DOI: 10.1186/s40478-018-0518-0  1
2018 Kay C, Collins JA, Wright GEB, Baine F, Miedzybrodzka Z, Aminkeng F, Semaka AJ, McDonald C, Davidson M, Madore SJ, Gordon ES, Gerry NP, Cornejo-Olivas M, Squitieri F, Tishkoff S, ... ... Hayden MR, et al. The molecular epidemiology of Huntington disease is related to intermediate allele frequency and haplotype in the general population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. PMID 29460498 DOI: 10.1002/ajmg.b.32618  1
2017 Garcia-Miralles M, Geva M, Tan JY, Yusof NABM, Cha Y, Kusko R, Tan LJ, Xu X, Grossman I, Orbach A, Hayden MR, Pouladi MA. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. Jci Insight. 2. PMID 29212949 DOI: 10.1172/jci.insight.95665  1
2017 Grossman I, Kolitz S, Komlosh A, Zeskind B, Weinstein V, Laifenfeld D, Gilbert A, Bar-Ilan O, Fowler KD, Hasson T, Konya A, Wells-Knecht K, Loupe P, Melamed-Gal S, Molotsky T, ... ... Hayden MR, et al. Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model. Annals of the New York Academy of Sciences. 1407: 75-89. PMID 29168242 DOI: 10.1111/nyas.13547  1
2017 Ehrnhoefer DE, Southwell AL, Sivasubramanian M, Qiu X, Villanueva EB, Xie Y, Waltl S, Anderson L, Fazeli A, Casal L, Felczak B, Tsang M, Hayden MR. HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo. Human Molecular Genetics. PMID 29121340 DOI: 10.1093/hmg/ddx394  1
2017 Kay C, Hayden MR, Leavitt BR. Epidemiology of Huntington disease. Handbook of Clinical Neurology. 144: 31-46. PMID 28947124 DOI: 10.1016/B978-0-12-801893-4.00003-1  1
2017 Trigueros-Motos L, van Capelleveen JC, Torta F, Castaño D, Zhang LH, Chai C, Kang M, Dimova LG, Schimmel AWM, Tietjen I, Radomski C, Tan LJ, Hwee TC, Narayanaswamy P, Wu D, ... ... Hayden MR, et al. ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels. Arteriosclerosis, Thrombosis, and Vascular Biology. PMID 28882873 DOI: 10.1161/ATVBAHA.117.309574  0.4
2017 Ross CJ, Towfic F, Shankar J, Laifenfeld D, Thoma M, Davis M, Weiner B, Kusko R, Zeskind B, Knappertz V, Grossman I, Hayden MR. A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. Genome Medicine. 9: 50. PMID 28569182 DOI: 10.1186/s13073-017-0436-y  1
2017 Southwell AL, Skotte NH, Villanueva EB, Østergaard ME, Gu X, Kordasiewicz HB, Kay C, Cheung D, Xie Y, Waltl S, Dal Cengio L, Findlay-Black H, Doty CN, Petoukhov E, Iworima D, ... ... Hayden MR, et al. A novel humanized mouse model of Huntington disease for preclinical development of therapeutics targeting mutant huntingtin alleles. Human Molecular Genetics. PMID 28104789 DOI: 10.1093/hmg/ddx021  1
2017 Hayden MR, Kay C. Author response: Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. 88: 334-335. PMID 28093515 DOI: 10.1212/WNL.0000000000003528  1
2016 Kay C, Tirado-Hurtado I, Cornejo-Olivas M, Collins JA, Wright G, Inca-Martinez M, Veliz-Otani D, Ketelaar ME, Slama RA, Ross CJ, Mazzetti P, Hayden MR. The targetable A1 Huntington disease haplotype has distinct Amerindian and European origins in Latin America. European Journal of Human Genetics : Ejhg. PMID 28000697 DOI: 10.1038/ejhg.2016.169  1
2016 Sanders SS, Parsons MP, Mui KK, Southwell AL, Franciosi S, Cheung D, Waltl S, Raymond LA, Hayden MR. Sudden death due to paralysis and synaptic and behavioral deficits when Hip14/Zdhhc17 is deleted in adult mice. Bmc Biology. 14: 108. PMID 27927242 DOI: 10.1186/s12915-016-0333-7  1
2016 Skotte NH, Sanders SS, Singaraja RR, Ehrnhoefer DE, Vaid K, Qiu X, Kannan S, Verma C, Hayden MR. Palmitoylation of caspase-6 by HIP14 regulates its activation. Cell Death and Differentiation. PMID 27911442 DOI: 10.1038/cdd.2016.139  1
2016 Kaye J, Piryatinsky V, Birnberg T, Hingaly T, Raymond E, Kashi R, Amit-Romach E, Caballero IS, Towfic F, Ator MA, Rubinstein E, Laifenfeld D, Orbach A, Shinar D, Marantz Y, ... ... Hayden MR, et al. Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. Proceedings of the National Academy of Sciences of the United States of America. PMID 27671624 DOI: 10.1073/pnas.1607843113  1
2016 Garcia-Miralles M, Hong X, Tan LJ, Caron NS, Huang Y, To XV, Lin RY, Franciosi S, Papapetropoulos S, Hayardeny L, Hayden MR, Chuang KH, Pouladi MA. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Scientific Reports. 6: 31652. PMID 27528441 DOI: 10.1038/srep31652  1
2016 Geva M, Kusko R, Soares H, Fowler K, Birnberg T, Barash S, Merenlender Wagner A, Fine T, Lysaght A, Weiner B, Cha Y, Kolitz S, Towfic F, Orbach A, Laufer R, ... ... Hayden MR, et al. Pridopidine activates neuroprotective pathways impaired in Huntington disease. Human Molecular Genetics. PMID 27466197 DOI: 10.1093/hmg/ddw238  1
2016 Southwell AL, Smith-Dijak A, Kay C, Sepers M, Villanueva EB, Parsons MP, Xie Y, Anderson L, Felczak B, Waltl S, Ko S, Cheung D, Dal Cengio L, Slama R, Petoukhov E, ... ... Hayden MR, et al. An enhanced Q175 knock-in mouse model of Huntington disease with higher mutant huntingtin levels and accelerated disease phenotypes. Human Molecular Genetics. PMID 27378694 DOI: 10.1093/hmg/ddw212  1
2016 Kay C, Collins JA, Miedzybrodzka Z, Madore SJ, Gordon ES, Gerry N, Davidson M, Slama RA, Hayden MR. Huntington disease reduced penetrance alleles occur at high frequency in the general population. Neurology. PMID 27335115 DOI: 10.1212/WNL.0000000000002858  1
2016 Ehrnhoefer DE, Caron NS, Deng Y, Qiu X, Tsang M, Hayden MR. Laquinimod decreases Bax expression and reduces caspase-6 activation in neurons. Experimental Neurology. PMID 27296315 DOI: 10.1016/j.expneurol.2016.06.008  1
2016 Maillet A, Tan K, Chai X, Sadananda SN, Mehta A, Ooi J, Hayden MR, Pouladi MA, Ghosh S, Shim W, Brunham LR. Modeling Doxorubicin-Induced Cardiotoxicity in Human Pluripotent Stem Cell Derived-Cardiomyocytes. Scientific Reports. 6: 25333. PMID 27142468 DOI: 10.1038/srep25333  0.52
2016 Teo RT, Hong X, Yu-Taeger L, Huang Y, Tan LJ, Xie Y, To XV, Guo L, Rajendran R, Novati A, Calaminus C, Riess O, Hayden MR, Nguyen HP, Chuang KH, et al. Structural and molecular myelination deficits occur prior to neuronal loss in the YAC128 and BACHD models of Huntington disease. Human Molecular Genetics. PMID 27126634 DOI: 10.1093/hmg/ddw122  1
2016 Miniarikova J, Zanella I, Huseinovic A, van der Zon T, Hanemaaijer E, Martier R, Koornneef A, Southwell AL, Hayden MR, van Deventer SJ, Petry H, Konstantinova P. Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. Molecular Therapy. Nucleic Acids. 5: e297. PMID 27003755 DOI: 10.1038/mtna.2016.7  1
2016 Riechers SP, Butland S, Deng Y, Skotte N, Ehrnhoefer DE, Russ J, Laine J, Laroche M, Pouladi MA, Wanker EE, Hayden MR, Graham RK. Interactome network analysis identifies multiple caspase-6 interactors involved in the pathogenesis of HD. Human Molecular Genetics. PMID 26908611 DOI: 10.1093/hmg/ddw036  1
2016 Garcia-Miralles M, Ooi J, Bardile CF, Tan LJ, George M, Drum CL, Lin RY, Hayden MR, Pouladi MA. Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease. Experimental Neurology. PMID 26825854 DOI: 10.1016/j.expneurol.2016.01.019  1
2016 Dobson L, Träger U, Farmer R, Hayardeny L, Loupe P, Hayden MR, Tabrizi SJ. Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells. Journal of Neurochemistry. PMID 26823290 DOI: 10.1111/jnc.13553  1
2016 Hasson T, Kolitz S, Towfic F, Laifenfeld D, Bakshi S, Beriozkin O, Shacham-Abramson M, Timan B, Fowler KD, Birnberg T, Konya A, Komlosh A, Ladkani D, Hayden MR, Zeskind B, et al. Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. Journal of Neuroimmunology. 290: 84-95. PMID 26711576 DOI: 10.1016/j.jneuroim.2015.11.020  1
2016 Hayden MR. A true mentor and pioneer in medical genetics South African Medical Journal. 106: S7-S9. DOI: 10.7196/SAMJ.2016.v106i6.11022  1
2015 Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, Nance M, Ross CA, Scahill RI, Wetzel R, Wild EJ, Tabrizi SJ. Huntington disease. Nature Reviews. Disease Primers. 1: 15005. PMID 27188817 DOI: 10.1038/nrdp.2015.5  1
2015 Patankar JV, Brunham LR, Hayden MR. Comment on Rickels et al. Loss-of-Function Mutations in ABCA1 and Enhanced β-Cell Secretory Capacity in Young Adults. Diabetes 2015;64:193-199. Diabetes. 64: e25-6; discussion e2. PMID 26294435 DOI: 10.2337/db15-0518  1
2015 Sanders SS, Martin DD, Butland SL, Lavallée-Adam M, Calzolari D, Kay C, Yates JR, Hayden MR. Curation of the Mammalian Palmitoylome Indicates a Pivotal Role for Palmitoylation in Diseases and Disorders of the Nervous System and Cancers. Plos Computational Biology. 11: e1004405. PMID 26275289 DOI: 10.1371/journal.pcbi.1004405  1
2015 Sadananda SN, Foo JN, Toh MT, Cermakova L, Trigueros-Motos L, Chan T, Liany H, Collins J, Germai S, Singaraja RR, Hayden MR, Francis GA, Frohlich J, Khor CC, Brunham LR. Targeted Next-Generation Sequencing to Diagnose Disorders of HDL Cholesterol. Journal of Lipid Research. PMID 26255038 DOI: 10.1194/jlr.P058891  1
2015 Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, ... Hayden MR, et al. A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer. Nature Genetics. PMID 26237429 DOI: 10.1038/ng.3374  1
2015 Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ. Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children. Pharmacogenomics. 16: 1065-76. PMID 26230641 DOI: 10.2217/pgs.15.61  1
2015 Kay C, Collins JA, Skotte NH, Southwell AL, Warby SC, Caron NS, Doty CN, Nguyen B, Griguoli A, Ross CJ, Squitieri F, Hayden MR. Huntingtin Haplotypes Provide Prioritized Target Panels for Allele-specific Silencing in Huntington Disease Patients of European Ancestry. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26201449 DOI: 10.1038/mt.2015.128  1
2015 Southwell AL, Smith SE, Davis TR, Caron NS, Villanueva EB, Xie Y, Collins JA, Li Ye M, Sturrock A, Leavitt BR, Schrum AG, Hayden MR. Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Scientific Reports. 5: 12166. PMID 26174131 DOI: 10.1038/srep12166  1
2015 Kolitz S, Hasson T, Towfic F, Funt JM, Bakshi S, Fowler KD, Laifenfeld D, Grinspan A, Artyomov MN, Birnberg T, Schwartz R, Komlosh A, Hayardeny L, Ladkani D, Hayden MR, et al. Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. Scientific Reports. 5: 10191. PMID 25998228 DOI: 10.1038/srep10191  1
2015 Jan A, Karasinska JM, Kang MH, de Haan W, Ruddle P, Kaur A, Connolly C, Leavitt BR, Sorensen PH, Hayden MR. Direct intracerebral delivery of a miR-33 antisense oligonucelotide into mouse brain increases brain ABCA1 expression. Neuroscience Letters. 598: 66-72. PMID 25957561 DOI: 10.1016/j.neulet.2015.05.007  1
2015 Bečanović K, Nørremølle A, Neal SJ, Kay C, Collins JA, Arenillas D, Lilja T, Gaudenzi G, Manoharan S, Doty CN, Beck J, Lahiri N, Portales-Casamar E, Warby SC, Connolly C, ... ... Hayden MR, et al. A SNP in the HTT promoter alters NF-κB binding and is a bidirectional genetic modifier of Huntington disease. Nature Neuroscience. 18: 807-16. PMID 25938884 DOI: 10.1038/nn.4014  1
2015 Stroedicke M, Bounab Y, Strempel N, Klockmeier K, Yigit S, Friedrich RP, Chaurasia G, Li S, Hesse F, Riechers SP, Russ J, Nicoletti C, Boeddrich A, Wiglenda T, Haenig C, ... ... Hayden MR, et al. Systematic interaction network filtering identifies CRMP1 as a novel suppressor of huntingtin misfolding and neurotoxicity. Genome Research. 25: 701-13. PMID 25908449 DOI: 10.1101/gr.182444.114  1
2015 Martin DD, Hayden MR. Post-translational myristoylation at the cross roads of cell death, autophagy and neurodegeneration. Biochemical Society Transactions. 43: 229-34. PMID 25849922 DOI: 10.1042/BST20140281  1
2015 Sanders SS, Hayden MR. Aberrant palmitoylation in Huntington disease. Biochemical Society Transactions. 43: 205-10. PMID 25849918 DOI: 10.1042/BST20140242  1
2015 Mattis VB, Tom C, Akimov S, Saeedian J, Østergaard ME, Southwell AL, Doty CN, Ornelas L, Sahabian A, Lenaeus L, Mandefro B, Sareen D, Arjomand J, Hayden MR, Ross CA, et al. HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Human Molecular Genetics. 24: 3257-71. PMID 25740845 DOI: 10.1093/hmg/ddv080  1
2015 Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Dar Santos R, Coleman AJ, Carter K, Creighton S, Bechtel N, Bohlen S, Reilmann R, Johnson HJ, Hayden MR, Tabrizi SJ, et al. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 393-401. PMID 25690257 DOI: 10.1002/mds.26118  1
2015 Southwell AL, Franciosi S, Villanueva EB, Xie Y, Winter LA, Veeraraghavan J, Jonason A, Felczak B, Zhang W, Kovalik V, Waltl S, Hall G, Pouladi MA, Smith ES, Bowers WJ, ... ... Hayden MR, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 76: 46-56. PMID 25662335 DOI: 10.1016/j.nbd.2015.01.002  1
2015 Østergaard ME, Thomas G, Koller E, Southwell AL, Hayden MR, Seth PP. Biophysical and biological characterization of hairpin and molecular beacon RNase H active antisense oligonucleotides. Acs Chemical Biology. 10: 1227-33. PMID 25654188 DOI: 10.1021/cb500880f  1
2015 Aharony I, Ehrnhoefer DE, Shruster A, Qiu X, Franciosi S, Hayden MR, Offen D. A Huntingtin-based peptide inhibitor of caspase-6 provides protection from mutant Huntingtin-induced motor and behavioral deficits. Human Molecular Genetics. 24: 2604-14. PMID 25616965 DOI: 10.1093/hmg/ddv023  1
2015 Brunham LR, Hayden MR. Human genetics of HDL: Insight into particle metabolism and function. Progress in Lipid Research. 58: 14-25. PMID 25601427 DOI: 10.1016/j.plipres.2015.01.001  1
2015 Wong BK, Ehrnhoefer DE, Graham RK, Martin DD, Ladha S, Uribe V, Stanek LM, Franciosi S, Qiu X, Deng Y, Kovalik V, Zhang W, Pouladi MA, Shihabuddin LS, Hayden MR. Partial rescue of some features of Huntington Disease in the genetic absence of caspase-6 in YAC128 mice. Neurobiology of Disease. 76: 24-36. PMID 25583186 DOI: 10.1016/j.nbd.2014.12.030  1
2015 Sanders SS, Hou J, Sutton LM, Garside VC, Mui KK, Singaraja RR, Hayden MR, Hoodless PA. Huntingtin interacting proteins 14 and 14-like are required for chorioallantoic fusion during early placental development. Developmental Biology. 397: 257-66. PMID 25478910 DOI: 10.1016/j.ydbio.2014.11.018  1
2015 Semaka A, Kay C, Belfroid RD, Bijlsma EK, Losekoot M, van Langen IM, van Maarle MC, Oosterloo M, Hayden MR, van Belzen MJ. A new mutation for Huntington disease following maternal transmission of an intermediate allele. European Journal of Medical Genetics. 58: 28-30. PMID 25464109 DOI: 10.1016/j.ejmg.2014.11.005  1
2015 Ooi J, Hayden MR, Pouladi MA. Inhibition of Excessive Monoamine Oxidase A/B Activity Protects Against Stress-induced Neuronal Death in Huntington Disease. Molecular Neurobiology. 52: 1850-61. PMID 25398695 DOI: 10.1007/s12035-014-8974-4  1
2015 Kaur A, Patankar JV, de Haan W, Ruddle P, Wijesekara N, Groen AK, Verchere CB, Singaraja RR, Hayden MR. Loss of Cyp8b1 improves glucose homeostasis by increasing GLP-1. Diabetes. 64: 1168-79. PMID 25338812 DOI: 10.2337/db14-0716  1
2015 Martin DD, Ladha S, Ehrnhoefer DE, Hayden MR. Autophagy in Huntington disease and huntingtin in autophagy. Trends in Neurosciences. 38: 26-35. PMID 25282404 DOI: 10.1016/j.tins.2014.09.003  1
2014 Skotte NH, Southwell AL, Østergaard ME, Carroll JB, Warby SC, Doty CN, Petoukhov E, Vaid K, Kordasiewicz H, Watt AT, Freier SM, Hung G, Seth PP, Bennett CF, Swayze EE, ... Hayden MR, et al. Allele-specific suppression of mutant huntingtin using antisense oligonucleotides: providing a therapeutic option for all Huntington disease patients. Plos One. 9: e107434. PMID 25207939 DOI: 10.1371/journal.pone.0107434  1
2014 Brown AM, Renaud Y, Ross C, Hansen M, Mongrain I, Valois D, Carleton BC, Hayden MR, Dubé MP, Tardif JC, Phillips MS. Development of a broad-based ADME panel for use in pharmacogenomic studies. Pharmacogenomics. 15: 1185-95. PMID 25141894 DOI: 10.2217/pgs.14.81  1
2014 Southwell AL, Skotte NH, Kordasiewicz HB, Østergaard ME, Watt AT, Carroll JB, Doty CN, Villanueva EB, Petoukhov E, Vaid K, Xie Y, Freier SM, Swayze EE, Seth PP, Bennett CF, ... Hayden MR, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2093-106. PMID 25101598 DOI: 10.1038/mt.2014.153  1
2014 Singaraja RR, Tietjen I, Hovingh GK, Franchini PL, Radomski C, Wong K, vanHeek M, Stylianou IM, Lin L, Wang L, Mitnaul L, Hubbard B, Winther M, Mattice M, Legendre A, ... ... Hayden MR, et al. Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. Journal of Lipid Research. 55: 1693-1701. PMID 24891332 DOI: 10.1194/jlr.M048710  1
2014 Kolodziejczyk K, Parsons MP, Southwell AL, Hayden MR, Raymond LA. Striatal synaptic dysfunction and hippocampal plasticity deficits in the Hu97/18 mouse model of Huntington disease. Plos One. 9: e94562. PMID 24728353 DOI: 10.1371/journal.pone.0094562  1
2014 Butland SL, Sanders SS, Schmidt ME, Riechers SP, Lin DT, Martin DD, Vaid K, Graham RK, Singaraja RR, Wanker EE, Conibear E, Hayden MR. The palmitoyl acyltransferase HIP14 shares a high proportion of interactors with huntingtin: implications for a role in the pathogenesis of Huntington's disease. Human Molecular Genetics. 23: 4142-60. PMID 24705354 DOI: 10.1093/hmg/ddu137  1
2014 Sanders SS, Mui KK, Sutton LM, Hayden MR. Identification of binding sites in Huntingtin for the Huntingtin Interacting Proteins HIP14 and HIP14L. Plos One. 9: e90669. PMID 24651384 DOI: 10.1371/journal.pone.0090669  1
2014 Kay C, Skotte NH, Southwell AL, Hayden MR. Personalized gene silencing therapeutics for Huntington disease. Clinical Genetics. 86: 29-36. PMID 24646433 DOI: 10.1111/cge.12385  1
2014 Rotblat B, Southwell AL, Ehrnhoefer DE, Skotte NH, Metzler M, Franciosi S, Leprivier G, Somasekharan SP, Barokas A, Deng Y, Tang T, Mathers J, Cetinbas N, Daugaard M, Kwok B, ... ... Hayden MR, et al. HACE1 reduces oxidative stress and mutant Huntingtin toxicity by promoting the NRF2 response. Proceedings of the National Academy of Sciences of the United States of America. 111: 3032-7. PMID 24516159 DOI: 10.1073/pnas.1314421111  1
2014 Martin DD, Heit RJ, Yap MC, Davidson MW, Hayden MR, Berthiaume LG. Identification of a post-translationally myristoylated autophagy-inducing domain released by caspase cleavage of huntingtin. Human Molecular Genetics. 23: 3166-79. PMID 24459296 DOI: 10.1093/hmg/ddu027  1
2014 Towfic F, Funt JM, Fowler KD, Bakshi S, Blaugrund E, Artyomov MN, Hayden MR, Ladkani D, Schwartz R, Zeskind B. Comparing the biological impact of glatiramer acetate with the biological impact of a generic. Plos One. 9: e83757. PMID 24421904 DOI: 10.1371/journal.pone.0083757  1
2014 Parsons MP, Kang R, Buren C, Dau A, Southwell AL, Doty CN, Sanders SS, Hayden MR, Raymond LA. Bidirectional control of postsynaptic density-95 (PSD-95) clustering by Huntingtin. The Journal of Biological Chemistry. 289: 3518-28. PMID 24347167 DOI: 10.1074/jbc.M113.513945  1
2014 Semaka A, Hayden MR. Evidence-based genetic counselling implications for Huntington disease intermediate allele predictive test results Clinical Genetics. 85: 303-311. PMID 24256063 DOI: 10.1111/cge.12324  1
2014 Fisher ER, Hayden MR. Multisource ascertainment of Huntington disease in Canada: prevalence and population at risk. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 105-14. PMID 24151181 DOI: 10.1002/mds.25717  1
2014 Ehrnhoefer DE, Skotte NH, Ladha S, Nguyen YT, Qiu X, Deng Y, Huynh KT, Engemann S, Nielsen SM, Becanovic K, Leavitt BR, Hasholt L, Hayden MR. p53 increases caspase-6 expression and activation in muscle tissue expressing mutant huntingtin. Human Molecular Genetics. 23: 717-29. PMID 24070868 DOI: 10.1093/hmg/ddt458  1
2014 Carleton BC, Ross CJ, Hayden MR. Genetic markers of cisplatin-induced hearing loss in children Clinical Advances in Hematology and Oncology. 12: 527-528.  1
2013 Stanek LM, Yang W, Angus S, Sardi PS, Hayden MR, Hung GH, Bennett CF, Cheng SH, Shihabuddin LS. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington's disease. Journal of Huntington's Disease. 2: 217-28. PMID 25063516 DOI: 10.3233/JHD-130057  1
2013 Milnerwood AJ, Parsons MP, Young FB, Singaraja RR, Franciosi S, Volta M, Bergeron S, Hayden MR, Raymond LA. Memory and synaptic deficits in Hip14/DHHC17 knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 110: 20296-301. PMID 24277827 DOI: 10.1073/pnas.1222384110  1
2013 Wan J, Savas JN, Roth AF, Sanders SS, Singaraja RR, Hayden MR, Yates JR, Davis NG. Tracking brain palmitoylation change: predominance of glial change in a mouse model of Huntington's disease. Chemistry & Biology. 20: 1421-34. PMID 24211138 DOI: 10.1016/j.chembiol.2013.09.018  1
2013 Franciosi S, Shim Y, Lau M, Hayden MR, Leavitt BR. A systematic review and meta-analysis of clinical variables used in Huntington disease research. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 1987-94. PMID 24142393 DOI: 10.1002/mds.25663  1
2013 Pouladi MA, Morton AJ, Hayden MR. Choosing an animal model for the study of Huntington's disease. Nature Reviews. Neuroscience. 14: 708-21. PMID 24052178 DOI: 10.1038/nrn3570  1
2013 Semaka A, Kay C, Doty CN, Collins JA, Tam N, Hayden MR. High frequency of intermediate alleles on Huntington disease-associated haplotypes in British Columbia's general population. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 162: 864-71. PMID 24038799 DOI: 10.1002/ajmg.b.32193  1
2013 Østergaard ME, Southwell AL, Kordasiewicz H, Watt AT, Skotte NH, Doty CN, Vaid K, Villanueva EB, Swayze EE, Bennett CF, Hayden MR, Seth PP. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS Nucleic Acids Research. 41: 9634-9650. PMID 23963702 DOI: 10.1093/nar/gkt725  1
2013 Bhavsar AP, Brown NF, Stoepel J, Wiermer M, Martin DD, Hsu KJ, Imami K, Ross CJ, Hayden MR, Foster LJ, Li X, Hieter P, Finlay BB. The Salmonella type III effector SspH2 specifically exploits the NLR co-chaperone activity of SGT1 to subvert immunity. Plos Pathogens. 9: e1003518. PMID 23935490 DOI: 10.1371/journal.ppat.1003518  1
2013 Kelly LE, Chaudhry SA, Rieder MJ, 't Jong G, Moretti ME, Lausman A, Ross C, Berger H, Carleton B, Hayden MR, Madadi P, Koren G. A clinical tool for reducing central nervous system depression among neonates exposed to codeine through breast milk. Plos One. 8: e70073. PMID 23922910 DOI: 10.1371/journal.pone.0070073  1
2013 Semaka A, Kay C, Doty C, Collins JA, Bijlsma EK, Richards F, Goldberg YP, Hayden MR. CAG size-specific risk estimates for intermediate allele repeat instability in Huntington disease. Journal of Medical Genetics. 50: 696-703. PMID 23896435 DOI: 10.1136/jmedgenet-2013-101796  1
2013 Marco S, Giralt A, Petrovic MM, Pouladi MA, Martínez-Turrillas R, Martínez-Hernández J, Kaltenbach LS, Torres-Peraza J, Graham RK, Watanabe M, Luján R, Nakanishi N, Lipton SA, Lo DC, Hayden MR, et al. Suppressing aberrant GluN3A expression rescues synaptic and behavioral impairments in Huntington's disease models. Nature Medicine. 19: 1030-8. PMID 23852340 DOI: 10.1038/nm.3246  1
2013 Shaw K, Amstutz U, Castro-Pastrana L, Loo TT, Ross CJ, Ito S, Reider MJ, Maher M, Macleod S, Koren G, Hayden MR, Carleton BC. Pharmacogenomic investigation of adverse drug reactions(ADRs): the ADR prioritization tool, APT. Journal of Population Therapeutics and Clinical Pharmacology = Journal De La ThéRapeutique Des Populations Et De La Pharamcologie Clinique. 20: e110-27. PMID 23824325  1
2013 Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, et al. Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset. Neurogenetics. 14: 173-9. PMID 23644918 DOI: 10.1007/s10048-013-0364-y  1
2013 Kastelein JJ, Ross CJ, Hayden MR. From mutation identification to therapy: discovery and origins of the first approved gene therapy in the Western world. Human Gene Therapy. 24: 472-8. PMID 23578007 DOI: 10.1089/hum.2013.063  1
2013 Rassekh SR, Ross CJ, Carleton BC, Hayden MR. Cancer pharmacogenomics in children: research initiatives and progress to date. Paediatric Drugs. 15: 71-81. PMID 23529868 DOI: 10.1007/s40272-013-0021-9  1
2013 Brunham LR, Hayden MR. Hunting human disease genes: lessons from the past, challenges for the future. Human Genetics. 132: 603-17. PMID 23504071 DOI: 10.1007/s00439-013-1286-3  1
2013 Baine FK, Kay C, Ketelaar ME, Collins JA, Semaka A, Doty CN, Krause A, Greenberg LJ, Hayden MR. Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. European Journal of Human Genetics : Ejhg. 21: 1120-7. PMID 23463025 DOI: 10.1038/ejhg.2013.2  1
2013 Karasinska JM, de Haan W, Franciosi S, Ruddle P, Fan J, Kruit JK, Stukas S, Lütjohann D, Gutmann DH, Wellington CL, Hayden MR. ABCA1 influences neuroinflammation and neuronal death. Neurobiology of Disease. 54: 445-55. PMID 23376685 DOI: 10.1016/j.nbd.2013.01.018  1
2013 Singaraja RR, Sivapalaratnam S, Hovingh K, Dubé MP, Castro-Perez J, Collins HL, Adelman SJ, Riwanto M, Manz J, Hubbard B, Tietjen I, Wong K, Mitnaul LJ, van Heek M, Lin L, ... ... Hayden MR, et al. The impact of partial and complete loss-of-function mutations in endothelial lipase on high-density lipoprotein levels and functionality in humans. Circulation. Cardiovascular Genetics. 6: 54-62. PMID 23243195 DOI: 10.1161/CIRCGENETICS.111.962613  1
2013 Virani AKH, Creighton SM, Hayden MR. Developing a comprehensive, effective patient-friendly website to enhance decision making in predictive testing for Huntington disease Genetics in Medicine. 15: 466-472. PMID 23222664 DOI: 10.1038/gim.2012.149  1
2013 Sutton LM, Sanders SS, Butland SL, Singaraja RR, Franciosi S, Southwell AL, Doty CN, Schmidt ME, Mui KK, Kovalik V, Young FB, Zhang W, Hayden MR. Hip14l-deficient mice develop neuropathological and behavioural features of Huntington disease. Human Molecular Genetics. 22: 452-65. PMID 23077216 DOI: 10.1093/hmg/dds441  1
2013 Southwell AL, Warby SC, Carroll JB, Doty CN, Skotte NH, Zhang W, Villanueva EB, Kovalik V, Xie Y, Pouladi MA, Collins JA, Yang XW, Franciosi S, Hayden MR. A fully humanized transgenic mouse model of Huntington disease. Human Molecular Genetics. 22: 18-34. PMID 23001568 DOI: 10.1093/hmg/dds397  1
2013 Semaka A, Balneaves LG, Hayden MR. "Grasping the grey": Patient understanding and interpretation of an intermediate allele predictive test result for huntington disease Journal of Genetic Counseling. 22: 200-217. PMID 22903792 DOI: 10.1007/s10897-012-9533-7  1
2013 Hawkins AK, Creighton S, Hayden MR. When access is an issue: exploring barriers to predictive testing for Huntington disease in British Columbia, Canada. European Journal of Human Genetics : Ejhg. 21: 148-53. PMID 22781094 DOI: 10.1038/ejhg.2012.147  1
2013 Hayden MR. Special new feature in Clinical Genetics Clinical Genetics. 83: 1. DOI: 10.1111/cge.12067  1
2012 Graham RK, Deng Y, Pouladi MA, Vaid K, Ehrnhoefer D, Southwell AL, Bissada N, Franciosi S, Hayden MR. Caspase-6-Resistant Mutant Huntingtin Does not Rescue the Toxic Effects of Caspase-Cleavable Mutant Huntingtin in vivo. Journal of Huntington's Disease. 1: 243-60. PMID 25063333 DOI: 10.3233/JHD-120038  1
2012 Strong MK, Southwell AL, Yonan JM, Hayden MR, Macgregor GR, Thompson LM, Steward O. Age-Dependent Resistance to Excitotoxicity in Htt CAG140 Mice and the Effect of Strain Background. Journal of Huntington's Disease. 1: 221-41. PMID 23833693 DOI: 10.3233/JHD-129005  1
2012 Southwell AL, Skotte NH, Bennett CF, Hayden MR. Antisense oligonucleotide therapeutics for inherited neurodegenerative diseases. Trends in Molecular Medicine. 18: 634-43. PMID 23026741 DOI: 10.1016/j.molmed.2012.09.001  1
2012 Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, et al. Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset. Human Genetics. 131: 1833-40. PMID 22825315 DOI: 10.1007/s00439-012-1205-z  1
2012 Pouladi MA, Brillaud E, Xie Y, Conforti P, Graham RK, Ehrnhoefer DE, Franciosi S, Zhang W, Poucheret P, Compte E, Maurel JC, Zuccato C, Cattaneo E, Néri C, Hayden MR. NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 48: 282-9. PMID 22796360 DOI: 10.1016/j.nbd.2012.06.026  1
2012 Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, et al. TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease. Biochemical and Biophysical Research Communications. 424: 404-8. PMID 22771793 DOI: 10.1016/j.bbrc.2012.06.120  1
2012 Brunham LR, Hayden MR. Medicine. Whole-genome sequencing: the new standard of care? Science (New York, N.Y.). 336: 1112-3. PMID 22654044 DOI: 10.1126/science.1220967  1
2012 Pouladi MA, Hayden MR. Polyglutamine diseases and the risk of cancer. The Lancet. Oncology. 13: 569-71. PMID 22652230 DOI: 10.1016/S1470-2045(12)70167-5  1
2012 Young FB, Franciosi S, Spreeuw A, Deng Y, Sanders S, Tam NC, Huang K, Singaraja RR, Zhang W, Bissada N, Kay C, Hayden MR. Low levels of human HIP14 are sufficient to rescue neuropathological, behavioural, and enzymatic defects due to loss of murine HIP14 in Hip14-/- mice. Plos One. 7: e36315. PMID 22649491 DOI: 10.1371/journal.pone.0036315  1
2012 Kelly LE, Rieder M, van den Anker J, Malkin B, Ross C, Neely MN, Carleton B, Hayden MR, Madadi P, Koren G. More codeine fatalities after tonsillectomy in North American children. Pediatrics. 129: e1343-7. PMID 22492761 DOI: 10.1542/peds.2011-2538  1
2012 Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Griguoli A, Di Donato S, Gomez-Tortosa E, Ayuso C, et al. Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region. American Journal of Human Genetics. 90: 434-44. PMID 22387017 DOI: 10.1016/j.ajhg.2012.01.005  1
2012 Pouladi MA, Stanek LM, Xie Y, Franciosi S, Southwell AL, Deng Y, Butland S, Zhang W, Cheng SH, Shihabuddin LS, Hayden MR. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Human Molecular Genetics. 21: 2219-32. PMID 22328089 DOI: 10.1093/hmg/dds037  1
2012 Kruit JK, Wijesekara N, Westwell-Roper C, Vanmierlo T, de Haan W, Bhattacharjee A, Tang R, Wellington CL, LütJohann D, Johnson JD, Brunham LR, Verchere CB, Hayden MR. Loss of both ABCA1 and ABCG1 results in increased disturbances in islet sterol homeostasis, inflammation, and impaired β-cell function. Diabetes. 61: 659-64. PMID 22315310 DOI: 10.2337/db11-1341  1
2012 Uribe V, Wong BK, Graham RK, Cusack CL, Skotte NH, Pouladi MA, Xie Y, Feinberg K, Ou Y, Ouyang Y, Deng Y, Franciosi S, Bissada N, Spreeuw A, Zhang W, ... ... Hayden MR, et al. Rescue from excitotoxicity and axonal degeneration accompanied by age-dependent behavioral and neuroanatomical alterations in caspase-6-deficient mice. Human Molecular Genetics. 21: 1954-67. PMID 22262731 DOI: 10.1093/hmg/dds005  1
2012 Bombard Y, Palin J, Friedman JM, Veenstra G, Creighton S, Bottorff JL, Hayden MR. Beyond the patient: the broader impact of genetic discrimination among individuals at risk of Huntington disease. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 159: 217-26. PMID 22231990 DOI: 10.1002/ajmg.b.32016  1
2012 Waldron-Roby E, Ratovitski T, Wang X, Jiang M, Watkin E, Arbez N, Graham RK, Hayden MR, Hou Z, Mori S, Swing D, Pletnikov M, Duan W, Tessarollo L, Ross CA. Transgenic mouse model expressing the caspase 6 fragment of mutant huntingtin. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 32: 183-93. PMID 22219281 DOI: 10.1523/JNEUROSCI.1305-11.2012  0.4
2012 Young FB, Butland SL, Sanders SS, Sutton LM, Hayden MR. Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases. Progress in Neurobiology. 97: 220-38. PMID 22155432 DOI: 10.1016/j.pneurobio.2011.11.002  1
2012 Ketelaar ME, Hofstra RMW, Hayden MR. What monozygotic twins discordant for phenotype illustrate about mechanisms influencing genetic forms of neurodegeneration Clinical Genetics. 81: 325-333. PMID 21981075 DOI: 10.1111/j.1399-0004.2011.01795.x  1
2012 Franciosi S, Ryu JK, Shim Y, Hill A, Connolly C, Hayden MR, McLarnon JG, Leavitt BR. Age-dependent neurovascular abnormalities and altered microglial morphology in the YAC128 mouse model of Huntington disease. Neurobiology of Disease. 45: 438-49. PMID 21946335 DOI: 10.1016/j.nbd.2011.09.003  1
2012 Bombard Y, Semaka A, Hayden MR. Adoption and the communication of genetic risk: Experiences in Huntington disease Clinical Genetics. 81: 64-69. PMID 21204796 DOI: 10.1111/j.1399-0004.2010.01614.x  1
2012 Brunham LR, Hayden MR. Response Science. 337: 911. DOI: 10.1126/science.337.6097.911-a  1
2011 Ehrnhoefer DE, Skotte NH, Savill J, Nguyen YT, Ladha S, Cao LP, Dullaghan E, Hayden MR. A quantitative method for the specific assessment of caspase-6 activity in cell culture. Plos One. 6: e27680. PMID 22140457 DOI: 10.1371/journal.pone.0027680  1
2011 Graham RK, Ehrnhoefer DE, Hayden MR. Caspase-6 and neurodegeneration. Trends in Neurosciences. 34: 646-56. PMID 22018804 DOI: 10.1016/j.tins.2011.09.001  1
2011 Ehrnhoefer DE, Wong BK, Hayden MR. Convergent pathogenic pathways in Alzheimer's and Huntington's diseases: shared targets for drug development. Nature Reviews. Drug Discovery. 10: 853-67. PMID 22015920 DOI: 10.1038/nrd3556  1
2011 Kruit JK, Wijesekara N, Fox JE, Dai XQ, Brunham LR, Searle GJ, Morgan GP, Costin AJ, Tang R, Bhattacharjee A, Johnson JD, Light PE, Marsh BJ, Macdonald PE, Verchere CB, ... Hayden MR, et al. Islet cholesterol accumulation due to loss of ABCA1 leads to impaired exocytosis of insulin granules. Diabetes. 60: 3186-96. PMID 21998401 DOI: 10.2337/db11-0081  1
2011 Carroll JB, Warby SC, Southwell AL, Doty CN, Greenlee S, Skotte N, Hung G, Bennett CF, Freier SM, Hayden MR. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene / allele-specific silencing of mutant huntingtin. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 2178-85. PMID 21971427 DOI: 10.1038/mt.2011.201  1
2011 Hawkins AK, Ho A, Hayden MR. Lessons from predictive testing for Huntington disease: 25 years on Journal of Medical Genetics. 48: 649-650. PMID 21931167 DOI: 10.1136/jmedgenet-2011-100352  1
2011 Karasinska JM, Hayden MR. Cholesterol metabolism in Huntington disease Nature Reviews Neurology. 7: 561-572. PMID 21894212 DOI: 10.1038/nrneurol.2011.132  1
2011 Carroll JB, Southwell AL, Graham RK, Lerch JP, Ehrnhoefer DE, Cao LP, Zhang WN, Deng Y, Bissada N, Henkelman RM, Hayden MR. Mice lacking caspase-2 are protected from behavioral changes, but not pathology, in the YAC128 model of Huntington disease. Molecular Neurodegeneration. 6: 59. PMID 21854568 DOI: 10.1186/1750-1326-6-59  1
2011 Song W, Chen J, Petrilli A, Liot G, Klinglmayr E, Zhou Y, Poquiz P, Tjong J, Pouladi MA, Hayden MR, Masliah E, Ellisman M, Rouiller I, Schwarzenbacher R, Bossy B, et al. Mutant huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nature Medicine. 17: 377-82. PMID 21336284 DOI: 10.1038/nm.2313  1
2011 Ehrnhoefer DE, Sutton L, Hayden MR. Small changes, big impact: Posttranslational modifications and function of huntingtin in huntington disease Neuroscientist. 17: 475-492. PMID 21311053 DOI: 10.1177/1073858410390378  1
2011 Hawkins AK, Hayden MR. A grand challenge: Providing benefits of clinical genetics to those in need Genetics in Medicine. 13: 197-200. PMID 21283011 DOI: 10.1097/GIM.0b013e31820c056e  1
2011 Simpson JM, Gil-Mohapel J, Pouladi MA, Ghilan M, Xie Y, Hayden MR, Christie BR. Altered adult hippocampal neurogenesis in the YAC128 transgenic mouse model of Huntington disease. Neurobiology of Disease. 41: 249-60. PMID 20875859 DOI: 10.1016/j.nbd.2010.09.012  1
2011 Bombard Y, Hayden MR. An interaction of genes in our social environment: Genetic discrimination among persons at risk for huntington disease Challenging Genetic Determinism: New Perspectives On the Gene in Its Multiple Environments. 182-203.  1
2010 Graham RK, Deng Y, Carroll J, Vaid K, Cowan C, Pouladi MA, Metzler M, Bissada N, Wang L, Faull RL, Gray M, Yang XW, Raymond LA, Hayden MR. Cleavage at the 586 amino acid caspase-6 site in mutant huntingtin influences caspase-6 activation in vivo. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 15019-29. PMID 21068307 DOI: 10.1523/JNEUROSCI.2071-10.2010  1
2010 Xie Y, Hayden MR, Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 30: 14708-18. PMID 21048129 DOI: 10.1523/JNEUROSCI.1637-10.2010  1
2010 Kang MH, Singaraja R, Hayden MR. Adenosine-triphosphate-binding cassette transporter-1 trafficking and function Trends in Cardiovascular Medicine. 20: 41-49. PMID 20656214 DOI: 10.1016/j.tcm.2010.03.006  1
2010 Kruit JK, Brunham LR, Verchere CB, Hayden MR. HDL and LDL cholesterol significantly influence β-cell function in type 2 diabetes mellitus Current Opinion in Lipidology. 21: 178-185. PMID 20463468 DOI: 10.1097/MOL.0b013e328339387b  1
2010 Brunham LR, Kruit JK, Hayden MR, Verchere CB. Cholesterol in β-cell dysfunction: The emerging connection between HDL cholesterol and type 2 diabetes Current Diabetes Reports. 10: 55-60. PMID 20425068 DOI: 10.1007/s11892-009-0090-x  1
2010 Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, Murphy TH, Raymond LA. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington's disease mice. Neuron. 65: 178-90. PMID 20152125 DOI: 10.1016/j.neuron.2010.01.008  1
2010 Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Human Molecular Genetics. 19: 1528-38. PMID 20097678 DOI: 10.1093/hmg/ddq026  1
2010 Becanovic K, Pouladi MA, Lim RS, Kuhn A, Pavlidis P, Luthi-Carter R, Hayden MR, Leavitt BR. Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis. Human Molecular Genetics. 19: 1438-52. PMID 20089533 DOI: 10.1093/hmg/ddq018  1
2010 Semaka A, Collins JA, Hayden MR. Unstable familial transmissions of Huntington disease alleles with 27-35 CAG repeats (intermediate alleles). American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 153: 314-20. PMID 19455596 DOI: 10.1002/ajmg.b.30970  1
2010 Kruit JK, Brunham LR, Verchere CB, Hayden MR. Cholesterol toxicity in pancreatic islets from LDL receptor-deficient mice. Reply to: De Souza JC, de Oliveira CAM, Carneiro em et al. [letter] Diabetologia. 53: 2463-2464. DOI: 10.1007/s00125-010-1877-7  1
2009 Okamoto S, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, Zhang D, Vincent Chen HS, Tong G, Hayden MR, Lipton SA. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nature Medicine. 15: 1407-13. PMID 19915593 DOI: 10.1038/nm.2056  1
2009 Macdonald ML, Bissada N, Vallance BA, Hayden MR. Absence of stearoyl-CoA desaturase-1 does not promote DSS-induced acute colitis. Biochimica Et Biophysica Acta. 1791: 1166-72. PMID 19695343 DOI: 10.1016/j.bbalip.2009.08.001  1
2009 Ehrnhoefer DE, Butland SL, Pouladi MA, Hayden MR. Mouse models of Huntington disease: Variations on a theme Dmm Disease Models and Mechanisms. 2: 123-129. PMID 19259385 DOI: 10.1242/dmm.002451  1
2009 Graham RK, Pouladi MA, Joshi P, Lu G, Deng Y, Wu NP, Figueroa BE, Metzler M, André VM, Slow EJ, Raymond L, Friedlander R, Levine MS, Leavitt BR, Hayden MR. Differential susceptibility to excitotoxic stress in YAC128 mouse models of Huntington disease between initiation and progression of disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 2193-204. PMID 19228972 DOI: 10.1523/JNEUROSCI.5473-08.2009  1
2009 Pouladi MA, Graham RK, Karasinska JM, Xie Y, Santos RD, Petersén A, Hayden MR. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain : a Journal of Neurology. 132: 919-32. PMID 19224899 DOI: 10.1093/brain/awp006  1
2009 MacDonald ML, van Eck M, Hildebrand RB, Wong BW, Bissada N, Ruddle P, Kontush A, Hussein H, Pouladi MA, Chapman MJ, Fievet C, van Berkel TJ, Staels B, McManus BM, Hayden MR. Despite antiatherogenic metabolic characteristics, SCD1-deficient mice have increased inflammation and atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 29: 341-7. PMID 19095997 DOI: 10.1161/ATVBAHA.108.181099  0.52
2008 Brunham LR, Kastelein JJP, Hayden MR. ABCA1 gene mutations, HDL cholesterol levels, and risk of ischemic heart disease Jama - Journal of the American Medical Association. 300: 1997-1998. PMID 18984885 DOI: 10.1001/jama.2008.539  1
2008 Björkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N, Raibon E, Lee RV, Benn CL, Soulet D, Magnusson A, Woodman B, Landles C, Pouladi MA, Hayden MR, et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. The Journal of Experimental Medicine. 205: 1869-77. PMID 18625748 DOI: 10.1084/jem.20080178  1
2008 Semaka A, Warby S, Leavitt BR, Hayden MR. Re: Autopsy-proven Huntington's disease with 29 trinucleotide repeats. Movement Disorders : Official Journal of the Movement Disorder Society. 23: 1794-5; author reply. PMID 18548612 DOI: 10.1002/mds.21820  1
2008 Brunham LR, Kruit JK, Verchere CB, Hayden MR. Cholesterol in islet dysfunction and type 2 diabetes Journal of Clinical Investigation. 118: 403-408. PMID 18246189 DOI: 10.1172/JCI33296  1
2008 Liu G, Hayden MR. Response to the letter by Ebara et al Circulation Research. 102. DOI: 10.1161/CIRCRESAHA.108.178715  1
2007 Orban P, Devon RS, Hayden MR, Leavitt BR. Chapter 15 Juvenile amyotrophic lateral sclerosis. Handbook of Clinical Neurology. 82: 301-12. PMID 18808900 DOI: 10.1016/S0072-9752(07)80018-2  1
2007 Gibson WT, Hayden MR. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Annals of the New York Academy of Sciences. 1110: 209-21. PMID 17911436 DOI: 10.1196/annals.1423.023  1
2007 Benn CL, Slow EJ, Farrell LA, Graham R, Deng Y, Hayden MR, Cha JH. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience. 147: 354-72. PMID 17544587 DOI: 10.1016/j.neuroscience.2007.03.010  1
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/hmg/ddm133  1
2007 Van Raamsdonk JM, Murphy Z, Selva DM, Hamidizadeh R, Pearson J, Petersén A, Björkqvist M, Muir C, Mackenzie IR, Hammond GL, Vogl AW, Hayden MR, Leavitt BR. Testicular degeneration in Huntington disease. Neurobiology of Disease. 26: 512-20. PMID 17433700 DOI: 10.1016/j.nbd.2007.01.006  1
2007 Ross CJ, Katzov H, Carleton B, Hayden MR. Pharmacogenomics and its implications for autoimmune disease. Journal of Autoimmunity. 28: 122-8. PMID 17418528 DOI: 10.1016/j.jaut.2007.02.008  1
2007 Van Raamsdonk JM, Warby SC, Hayden MR. Selective degeneration in YAC mouse models of Huntington disease Brain Research Bulletin. 72: 124-131. PMID 17352936 DOI: 10.1016/j.brainresbull.2006.10.018  1
2007 Van Raamsdonk JM, Metzler M, Slow E, Pearson J, Schwab C, Carroll J, Graham RK, Leavitt BR, Hayden MR. Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain. Neurobiology of Disease. 26: 189-200. PMID 17276692 DOI: 10.1016/j.nbd.2006.12.010  1
2006 Van Raamsdonk JM, Pearson J, Murphy Z, Hayden MR, Leavitt BR. Wild-type huntingtin ameliorates striatal neuronal atrophy but does not prevent other abnormalities in the YAC128 mouse model of Huntington disease. Bmc Neuroscience. 7: 80. PMID 17147801 DOI: 10.1186/1471-2202-7-80  1
2006 Zhang Y, Leavitt BR, van Raamsdonk JM, Dragatsis I, Goldowitz D, MacDonald ME, Hayden MR, Friedlander RM. Huntingtin inhibits caspase-3 activation. The Embo Journal. 25: 5896-906. PMID 17124493 DOI: 10.1038/sj.emboj.7601445  1
2006 Leavitt BR, Hayden MR. Is tetrabenazine safe and effective for suppressing chorea in Huntington's disease? Nature Clinical Practice. Neurology. 2: 536-7. PMID 16990826 DOI: 10.1038/ncpneuro0299  1
2006 Slow EJ, Graham RK, Hayden MR. To be or not to be toxic: aggregations in Huntington and Alzheimer disease. Trends in Genetics : Tig. 22: 408-11. PMID 16806565 DOI: 10.1016/j.tig.2006.05.008  1
2006 Graham RK, Deng Y, Slow EJ, Haigh B, Bissada N, Lu G, Pearson J, Shehadeh J, Bertram L, Murphy Z, Warby SC, Doty CN, Roy S, Wellington CL, Leavitt BR, ... ... Hayden MR, et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell. 125: 1179-91. PMID 16777606 DOI: 10.1016/j.cell.2006.04.026  1
2006 Brunham LR, Singaraja RR, Hayden MR. Variations on a gene: rare and common variants in ABCA1 and their impact on HDL cholesterol levels and atherosclerosis Annual Review of Nutrition. 26: 105-129. PMID 16704350 DOI: 10.1146/annurev.nutr.26.061505.111214  1
2006 Guidetti P, Bates GP, Graham RK, Hayden MR, Leavitt BR, MacDonald ME, Slow EJ, Wheeler VC, Woodman B, Schwarcz R. Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiology of Disease. 23: 190-7. PMID 16697652 DOI: 10.1016/j.nbd.2006.02.011  1
2006 Van Raamsdonk JM, Gibson WT, Pearson J, Murphy Z, Lu G, Leavitt BR, Hayden MR. Body weight is modulated by levels of full-length huntingtin. Human Molecular Genetics. 15: 1513-23. PMID 16571604 DOI: 10.1093/hmg/ddl072  1
2006 Leavitt BR, van Raamsdonk JM, Shehadeh J, Fernandes H, Murphy Z, Graham RK, Wellington CL, Raymond LA, Hayden MR. Wild-type huntingtin protects neurons from excitotoxicity. Journal of Neurochemistry. 96: 1121-9. PMID 16417581 DOI: 10.1111/j.1471-4159.2005.03605.x  1
2006 Graham RK, Slow EJ, Deng Y, Bissada N, Lu G, Pearson J, Shehadeh J, Leavitt BR, Raymond LA, Hayden MR. Levels of mutant huntingtin influence the phenotypic severity of Huntington disease in YAC128 mouse models. Neurobiology of Disease. 21: 444-55. PMID 16230019 DOI: 10.1016/j.nbd.2005.08.007  1
2006 Pouladi MA, Bezprozvanny I, Raymond LA, Hayden MR. Molecular pathogenesis of Huntington's disease: The role of excitotoxicity Genetic Instabilities and Neurological Diseases, Second Edition. 251-260. DOI: 10.1016/B978-012369462-1/50016-8  1
2005 Hayden MR, Bombard Y. Psychosocial effects of predictive testing for Huntington's disease Advances in Neurology. 96: 226-239. PMID 16383222  1
2005 Van Raamsdonk JM, Murphy Z, Slow EJ, Leavitt BR, Hayden MR. Selective degeneration and nuclear localization of mutant huntingtin in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 3823-35. PMID 16278236 DOI: 10.1093/hmg/ddi407  1
2005 Van Raamsdonk JM, Pearson J, Bailey CD, Rogers DA, Johnson GV, Hayden MR, Leavitt BR. Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease. Journal of Neurochemistry. 95: 210-20. PMID 16181425 DOI: 10.1111/j.1471-4159.2005.03357.x  1
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, Honer WG, Hayden MR, Leavitt BR. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology. 196: 266-72. PMID 16129433 DOI: 10.1016/j.expneurol.2005.07.021  1
2005 Slow EJ, Graham RK, Osmand AP, Devon RS, Lu G, Deng Y, Pearson J, Vaid K, Bissada N, Wetzel R, Leavitt BR, Hayden MR. Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions. Proceedings of the National Academy of Sciences of the United States of America. 102: 11402-7. PMID 16076956 DOI: 10.1073/pnas.0503634102  1
2005 Pinto JT, Van Raamsdonk JM, Leavitt BR, Hayden MR, Jeitner TM, Thaler HT, Krasnikov BF, Cooper AJ. Treatment of YAC128 mice and their wild-type littermates with cystamine does not lead to its accumulation in plasma or brain: implications for the treatment of Huntington disease. Journal of Neurochemistry. 94: 1087-101. PMID 15992377 DOI: 10.1111/j.1471-4159.2005.03255.x  1
2005 Van Raamsdonk JM, Pearson J, Slow EJ, Hossain SM, Leavitt BR, Hayden MR. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 25: 4169-80. PMID 15843620 DOI: 10.1523/JNEUROSCI.0590-05.2005  1
2005 Van Raamsdonk JM, Pearson J, Rogers DA, Bissada N, Vogl AW, Hayden MR, Leavitt BR. Loss of wild-type huntingtin influences motor dysfunction and survival in the YAC128 mouse model of Huntington disease. Human Molecular Genetics. 14: 1379-92. PMID 15829505 DOI: 10.1093/hmg/ddi147  1
2005 Hayden MR, Biesecker B. Introduction to Social and Behavioural Research in genetics Clinical Genetics. 67: 480. DOI: 10.1111/j.1399-0004.2005.00464.x  1
2005 Van Raamsdonk JM, Hayden MR, Leavitt BR. Experimental models of Huntington's disease Drug Discovery Today: Disease Models. 2: 291-297. DOI: 10.1016/j.ddmod.2005.11.010  1
2004 Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochemical and Biophysical Research Communications. 322: 1310-7. PMID 15336977 DOI: 10.1016/j.bbrc.2004.08.035  1
2004 Li L, Murphy TH, Hayden MR, Raymond LA. Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease. Journal of Neurophysiology. 92: 2738-46. PMID 15240759 DOI: 10.1152/jn.00308.2004  1
2004 Lafreniere RG, MacDonald ML, Dube MP, MacFarlane J, O'Driscoll M, Brais B, Meilleur S, Brinkman RR, Dadivas O, Pape T, Platon C, Radomski C, Risler J, Thompson J, Guerra-Escobio AM, ... ... Hayden MR, et al. Identification of a novel gene (HSN2) causing hereditary sensory and autonomic neuropathy type II through the Study of Canadian Genetic Isolates. American Journal of Human Genetics. 74: 1064-73. PMID 15060842 DOI: 10.1086/420795  1
2004 Djoussé L, Knowlton B, Hayden MR, Almqvist EW, Brinkman RR, Ross CA, Margolis RL, Rosenblatt A, Durr A, Dode C, Morrison PJ, Novelletto A, Frontali M, Trent RJ, McCusker E, et al. Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16. Neurogenetics. 5: 109-14. PMID 15029481 DOI: 10.1007/s10048-004-0175-2  1
2004 Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR. A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clinical Genetics. 65: 267-77. PMID 15025718 DOI: 10.1111/j.1399-0004.2004.00241.x  1
2003 Brunham LR, Hayden MR. Clarity is essential when using Nucleotide number systems Atherosclerosis. 170: 349. PMID 14612218 DOI: 10.1016/S0021-9150(03)00234-X  1
2003 Almqvist EW, Brinkman RR, Wiggins S, Hayden MR. Psychological consequences and predictors of adverse events in the first 5 years after predictive testing for Huntington's disease. Clinical Genetics. 64: 300-9. PMID 12974735 DOI: 10.1034/j.1399-0004.2003.00157.x  1
2003 Li JL, Hayden MR, Almqvist EW, Brinkman RR, Durr A, Dodé C, Morrison PJ, Suchowersky O, Ross CA, Margolis RL, Rosenblatt A, Gómez-Tortosa E, Cabrero DM, Novelletto A, Frontali M, et al. A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study. American Journal of Human Genetics. 73: 682-7. PMID 12900792 DOI: 10.1086/378133  1
2003 Hayden MR. Predictive testing for Huntington's disease: A universal model? Lancet Neurology. 2: 141-142. PMID 12849232 DOI: 10.1016/S1474-4422(03)00317-X  1
2003 Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, Li XJ, Simpson EM, Gutekunst CA, Leavitt BR, Hayden MR. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Human Molecular Genetics. 12: 1555-67. PMID 12812983 DOI: 10.1093/hmg/ddg169  1
2003 Wellington CL, Hayden MR. Preface Clinical Neuroscience Research. 3: 119-120. DOI: 10.1016/S1566-2772(03)00053-7  1
2002 Wellington CL, Yang YZ, Zhou S, Clee SM, Tan B, Hirano K, Zwarts K, Kwok A, Gelfer A, Marcil M, Newman S, Roomp K, Singaraja R, Collins J, Zhang LH, ... ... Hayden MR, et al. Truncation mutations in ABCA1 suppress normal upregulation of full-length ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. Journal of Lipid Research. 43: 1939-49. PMID 12401893 DOI: 10.1194/jlr.M200277-JLR200  1
2002 Singaraja RR, Fievet C, Castro G, James ER, Hennuyer N, Clee SM, Bissada N, Choy JC, Fruchart JC, McManus BM, Staels B, Hayden MR. Increased ABCA1 activity protects against atherosclerosis. The Journal of Clinical Investigation. 110: 35-42. PMID 12093886 DOI: 10.1172/JCI15748  0.4
2002 Zwarts KY, Clee SM, Zwinderman AH, Engert JC, Singaraja R, Loubser O, James E, Roomp K, Hudson TJ, Jukema JW, Kastelein JJ, Hayden MR. ABCA1 regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. Clinical Genetics. 61: 115-25. PMID 11940086  0.4
2002 van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, Zwinderman AH, Smit AJ, Smelt AH, Groen AK, Hayden MR, Kastelein JJ. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet (London, England). 359: 37-42. PMID 11809185 DOI: 10.1016/S0140-6736(02)07277-X  0.4
2001 Attie AD, Kastelein JP, Hayden MR. Pivotal role of ABCA1 in reverse cholesterol transport influencing HLD levels and susceptibility to atherosclerosis Journal of Lipid Research. 42: 1717-1726. PMID 11714841  1
2001 Clee SM, Loubser O, Collins J, Kastelein JJ, Hayden MR. The LPL S447X cSNP is associated with decreased blood pressure and plasma triglycerides, and reduced risk of coronary artery disease. Clinical Genetics. 60: 293-300. PMID 11683775  0.4
2001 Almqvist EW, Elterman DS, MacLeod PM, Hayden MR. High incidence rate and absent family histories in one quarter of patients newly diagnosed with Huntington disease in British Columbia Clinical Genetics. 60: 198-205. PMID 11595021 DOI: 10.1034/j.1399-0004.2001.600305.x  1
2001 Paulsen JS, Zhao H, Stout JC, Brinkman RR, Guttman M, Ross CA, Como P, Manning C, Hayden MR, Shoulson I. Clinical markers of early disease in persons near onset of Huntington's disease. Neurology. 57: 658-62. PMID 11524475  1
2001 Rosenblatt A, Brinkman RR, Liang KY, Almqvist EW, Margolis RL, Huang CY, Sherr M, Franz ML, Abbott MH, Hayden MR, Ross CA. Familial influence on age of onset among siblings with Huntington disease. American Journal of Medical Genetics. 105: 399-403. PMID 11449389 DOI: 10.1002/ajmg.1400  1
2001 Singaraja RR, Bocher V, James ER, Clee SM, Zhang LH, Leavitt BR, Tan B, Brooks-Wilson A, Kwok A, Bissada N, Yang YZ, Liu G, Tafuri SR, Fievet C, Wellington CL, ... ... Hayden MR, et al. Human ABCA1 BAC transgenic mice show increased high density lipoprotein cholesterol and ApoAI-dependent efflux stimulated by an internal promoter containing liver X receptor response elements in intron 1. The Journal of Biological Chemistry. 276: 33969-79. PMID 11423537 DOI: 10.1074/jbc.M102503200  1
2001 McGladdery SH, Pimstone SN, Clee SM, Bowden JF, Hayden MR, Frohlich JJ. Common mutations in the lipoprotein lipase gene (LPL): effects on HDL-cholesterol levels in a Chinese Canadian population. Atherosclerosis. 156: 401-7. PMID 11395037  0.4
2001 Clee SM, Zwinderman AH, Engert JC, Zwarts KY, Molhuizen HO, Roomp K, Jukema JW, van Wijland M, van Dam M, Hudson TJ, Brooks-Wilson A, Genest J, Kastelein JJ, Hayden MR. Common genetic variation in ABCA1 is associated with altered lipoprotein levels and a modified risk for coronary artery disease. Circulation. 103: 1198-205. PMID 11238261  0.4
2001 Backus RC, Ginzinger DG, Ashbourne Excoffon KJ, Clee SM, Hayden MR, Eckel RH, Hickman MA, Rogers QR. Maternal expression of functional lipoprotein lipase and effects on body fat mass and body condition scores of mature cats with lipoprotein lipase deficiency. American Journal of Veterinary Research. 62: 264-9. PMID 11212037  1
2000 Hayden MR, Ling V. Michael Smith (1932-2000). Nature. 408: 786. PMID 11147530 DOI: 10.1038/35048663  1
2000 Hayden MR. Predictive testing for Huntington's disease: The calm after the storm Lancet. 356: 1944-1945. PMID 11130517 DOI: 10.1016/S0140-6736(00)03301-8  1
2000 Wellington CL, Leavitt BR, Hayden MR. Huntington disease: new insights on the role of huntingtin cleavage. Journal of Neural Transmission. Supplementum. 1-17. PMID 11128600  1
2000 Clee SM, Kastelein JJ, van Dam M, Marcil M, Roomp K, Zwarts KY, Collins JA, Roelants R, Tamasawa N, Stulc T, Suda T, Ceska R, Boucher B, Rondeau C, DeSouich C, ... ... Hayden MR, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1 heterozygotes. The Journal of Clinical Investigation. 106: 1263-70. PMID 11086027 DOI: 10.1172/JCI10727  0.4
2000 Hayden MR, Clee SM, Brooks-Wilson A, Genest J, Attie A, Kastelein JJ. Cholesterol efflux regulatory protein, Tangier disease and familial high-density lipoprotein deficiency. Current Opinion in Lipidology. 11: 117-22. PMID 10787172  0.4
2000 Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, Steures P, McManus J, McManus B, LeBoeuf RC, Kastelein JJ, Hayden MR. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. Journal of Lipid Research. 41: 521-31. PMID 10744772  1
2000 Wellington CL, Hayden MR. Caspases and neurodegeneration: on the cutting edge of new therapeutic approaches. Clinical Genetics. 57: 1-10. PMID 10733228 DOI: 10.1034/j.1399-0004.2000.570101.x  1
2000 Liu G, Ashbourne Excoffon KJ, Wilson JE, McManus BM, Rogers QR, Miao L, Kastelein JJ, Lewis ME, Hayden MR. Phenotypic correction of feline lipoprotein lipase deficiency by adenoviral gene transfer. Human Gene Therapy. 11: 21-32. PMID 10646636 DOI: 10.1089/10430340050016120  1
1999 Leavitt BR, Wellington CL, Hayden MR. Recent insights into the molecular pathogenesis of Huntington disease. Seminars in Neurology. 19: 385-95. PMID 10716661 DOI: 10.1055/s-2008-1040853  1
1999 Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, Collins JA, van Dam M, Molhuizen HO, Loubster O, Ouellette BF, Sensen CW, Fichter K, Mott S, Denis M, ... ... Hayden MR, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 354: 1341-6. PMID 10533863  0.4
1999 Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, Yu L, Brewer C, Collins JA, Molhuizen HO, Loubser O, Ouelette BF, Fichter K, Ashbourne-Excoffon KJ, Sensen CW, ... ... Hayden MR, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genetics. 22: 336-45. PMID 10431236 DOI: 10.1038/11905  0.4
1999 Ginzinger DG, Clee SM, Dallongeville J, Lewis ME, Henderson HE, Bauje E, Rogers QR, Jensen DR, Eckel RH, Dyer R, Innis S, Jones B, Fruchart JC, Hayden MR. Lipid and lipoprotein analysis of cats with lipoprotein lipase deficiency. European Journal of Clinical Investigation. 29: 17-26. PMID 10092984 DOI: 10.1046/j.1365-2362.1999.00435.x  1
1999 Hadano S, Nichol K, Brinkman RR, Nasir J, Martindale D, Koop BF, Nicholson DW, Scherer SW, Ikeda JE, Hayden MR. A yeast artificial chromosome-based physical map of the juvenile amyotrophic lateral sclerosis (ALS2) critical region on human chromosome 2q33-q34. Genomics. 55: 106-12. PMID 9889004 DOI: 10.1006/geno.1998.5637  1
1998 Hayden MR. In vitro and in vivo models for Huntington disease: Lessons for the polyglutamine expansion disorders Pathologie Biologie. 46: 695. PMID 9885820  1
1998 Hackam AS, Wellington CL, Hayden MR. The fatal attraction of polyglutamine-containing proteins. Clinical Genetics. 53: 233-42. PMID 9650759  1
1998 Hayden MR. The new clinical genetics: Towards the millennium Clinical Genetics. 53: 1-2. DOI: 10.1034/j.1399-0004.1998.531530101.x  1
1997 Ehrenborg E, Clee SM, Pimstone SN, Reymer PW, Benlian P, Hoogendijk CF, Davis HJ, Bissada N, Miao L, Gagné SE, Greenberg LJ, Henry R, Henderson H, Ordovas JM, Schaefer EJ, ... ... Hayden MR, et al. Ethnic variation and in vivo effects of the -93t-->g promoter variant in the lipoprotein lipase gene. Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 2672-8. PMID 9409241  0.4
1997 Ginzinger DG, Wilson JE, Redenbach D, Lewis ME, Clee SM, Excoffon KJ, Rogers QR, Hayden MR, McManus BM. Diet-induced atherosclerosis in the domestic cat. Laboratory Investigation; a Journal of Technical Methods and Pathology. 77: 409-19. PMID 9389784  1
1997 Clee SM, Zhang H, Bissada N, Miao L, Ehrenborg E, Benlian P, Shen GX, Angel A, LeBoeuf RC, Hayden MR. Relationship between lipoprotein lipase and high density lipoprotein cholesterol in mice: modulation by cholesteryl ester transfer protein and dietary status. Journal of Lipid Research. 38: 2079-89. PMID 9374130  1
1997 Andrew SE, Goldberg YP, Hayden MR. Rethinking genotype and phenotype correlations in polyglutamine expansion disorders Human Molecular Genetics. 6: 2005-2010. PMID 9328463 DOI: 10.1093/hmg/6.12.2005  1
1997 Wellington CL, Hayden MR. Of molecular interactions, mice and mechanisms: New insights into Huntington's disease Current Opinion in Neurology. 10: 291-298. PMID 9266152  1
1997 Wellington CL, Brinkman RR, O'Kusky JR, Hayden MR. Toward understanding the molecular pathology of Huntington's disease. Brain Pathology (Zurich, Switzerland). 7: 979-1002. PMID 9217979  1
1997 Burgess MM, Adam S, Bloch M, Hayden MR. Dilemmas of anonymous predictive testing for Huntington disease: Privacy vs. optimal care American Journal of Medical Genetics. 71: 197-201. PMID 9217222 DOI: 10.1002/(SICI)1096-8628(19970808)71:2<197::AID-AJMG15>3.0.CO;2-9  1
1997 Pimstone SN, Defesche JC, Clee SM, Bakker HD, Hayden MR, Kastelein JJ. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia. Arteriosclerosis, Thrombosis, and Vascular Biology. 17: 826-33. PMID 9157944  0.4
1997 Brinkman RR, Mezei MM, Theilmann J, Almqvist E, Hayden MR. The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. American Journal of Human Genetics. 60: 1202-10. PMID 9150168  1
1997 Pedro-Botet J, Rubies-Prat J, Benlian P, Hayden MR. Premature atherosclerosis in familial chylomicronemia [5] New England Journal of Medicine. 336: 1026-1027. PMID 9091793 DOI: 10.1056/NEJM199704033361416  1
1996 Wiggins S, Green T, Adam S, Hayden MR. A long term (ca 5 years) prospective assessment of psychological consequences of predictive testing for Huntington disease (HD) American Journal of Human Genetics. 59. PMID 11644838  1
1996 Nasir J, Goldberg YP, Hayden MR. Huntington disease: New insights into the relationship between CAG expansion and disease Human Molecular Genetics. 5: 1431-1435. PMID 8875248  1
1996 Pimstone SN, Clee SM, Gagné SE, Miao L, Zhang H, Stein EA, Hayden MR. A frequently occurring mutation in the lipoprotein lipase gene (Asn291Ser) results in altered postprandial chylomicron triglyceride and retinyl palmitate response in normolipidemic carriers. Journal of Lipid Research. 37: 1675-84. PMID 8864951  0.4
1996 Henderson HE, Hassan F, Marais D, Hayden MR. A new mutation destroying disulphide bridging in the C-terminal domain of lipoprotein lipase Biochemical and Biophysical Research Communications. 227: 189-194. PMID 8858123 DOI: 10.1006/bbrc.1996.1487  1
1996 Squitieri F, Campanella G, Hayden MR. Update on genetics of Huntington's disease: availability of direct and accurate predictive test Italian Journal of Neurological Sciences. 17: 185-187. PMID 8856407  1
1996 Burgess MM, Hayden MR. Patients' rights to laboratory data: Trinucleotide repeat length in huntington disease American Journal of Medical Genetics. 62: 6-9. PMID 8779327  1
1996 Zhang H, Henderson H, Gagne SE, Clee SM, Miao L, Liu G, Hayden MR. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochimica Et Biophysica Acta. 1302: 159-66. PMID 8695666  0.4
1996 Nevin DN, Deeb SS, Hayden MR, Brunzell JD. Heterozygous mutations in the lipoprotein lipase gene contribute to chylomicronemia in the adult Journal of Investigative Medicine. 44.  1
1995 Andrew SE, Hayden MR. Origins and evolution of huntington disease chromosomes Neurodegeneration. 4: 239-244. PMID 8581556 DOI: 10.1016/1055-8330(95)90013-6  1
1995 Hayden MR, Bloch M, Wiggins S. Psychological effects of predictive testing for Huntington's disease Advances in Neurology. 65: 201-210. PMID 7872141  1
1995 Hayden MR, Reidy M. Many roads lead to atheroma Nature Medicine. 1: 22-23. PMID 7584946 DOI: 10.1038/nm0195-22  1
1994 Hayden MR, Liu MS, Ma Y. Gene environment interaction and plasma triglyceride levels: The crucial role of lipoprotein lipase Clinical Genetics. 46: 15-18. PMID 7988072  1
1994 Goldberg YP, Telenius H, Hayden MR. The molecular genetics of Huntington's disease Current Opinion in Neurology. 7: 325-332. PMID 7952241  1
1994 Clark CM, Kremer B, Hayden MR. Regional cerebral glucose metabolism in Huntington's disease: A statistical investigation Human Brain Mapping. 2: 95-102.  1
1993 Hayden MR. On planting alfalfa and growing orchids: The cloning of the gene causing Huntington disease Clinical Genetics. 43: 217-222. PMID 8375101  1
1993 Goldberg YP, Andrew SE, Clarke LA, Hayden MR. A PCR method for accurate assessment of trinucleotide repeat expansion in huntington disease Human Molecular Genetics. 2: 635-636. PMID 8353482 DOI: 10.1093/hmg/2.6.635  1
1993 Durbach N, Hayden MR. George Huntington: the man behind the eponym. Journal of Medical Genetics. 30: 406-9. PMID 8320704  1
1993 Hayden MR, Josephson R. Development of a program for identification of patients with familial hypercholesterolemia in British Columbia: A model for prevention of coronary disease The American Journal of Cardiology. 72: D25-D29. PMID 8213493 DOI: 10.1016/0002-9149(93)90007-Y  1
1993 McGeer EG, Kremer B, Hayden MR. Monoamines and their metabolites in Huntington's disease brain: Evidence for decreased catechol-O-methyltransferase activity Biological Psychiatry. 33: 551-553. PMID 8099814 DOI: 10.1016/0006-3223(93)90012-3  1
1992 Hayden MR, Ma Y. Molecular genetics of human lipoprotein lipase deficiency Molecular and Cellular Biochemistry. 113: 171-176. PMID 1518507 DOI: 10.1007/BF00231536  1
1992 Liu MS, Ma Y, Hayden MR, Brunzell JD. Mapping of the epitope on lipoprotein lipase recognized by a monoclonal antibody (5D2) which inhibits lipase activity Biochimica Et Biophysica Acta (Bba)/Lipids and Lipid Metabolism. 1128: 113-115. PMID 1382603 DOI: 10.1016/0005-2760(92)90264-V  1
1992 Henderson HE, Hassan F, Berger GMB, Hayden MR. The lipoprotein lipase Gly188→Glu mutation in South Africans of Indian descent: Evidence suggesting common origins and an increased frequency Journal of Medical Genetics. 29: 119-122. PMID 1351946  1
1992 Kremer B, Weber B, Hayden MR. New insights into the clinical features, pathogenesis and molecular genetics of huntington disease Brain Pathology. 2: 321-335. PMID 1341966  1
1992 Riess O, Weber B, Hayden MR. (CA)n-dinucleotide repeat polymorphism at the locus for the alpha2c adrenergic receptor (ADRA2C) on 4p16 Human Molecular Genetics. 1: 452. PMID 1338762 DOI: 10.1093/hmg/1.6.452  1
1992 Hutchinson GB, Hayden MR. The prediction of exons through an analysis of spliceable open reading frames Nucleic Acids Research. 20: 3453-3462. PMID 1321415 DOI: 10.1093/nar/20.13.3453  1
1992 Collins C, Schappert K, Hayden MR. The genomic organization of a novel regulatory myosin light chain gene (MYL5) that maps to chromosome 4p16.3 and shows different patterns of expression between primates Human Molecular Genetics. 1: 727-733. PMID 1284596  1
1991 Hill JS, Hayden MR, Frohlich J, Pritchard PH. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia Arteriosclerosis, Thrombosis, and Vascular Biology. 11: 290-297. PMID 1998646  1
1991 Hayden MR. Predictive testing for Huntington disease: Are we ready for widespread community implementation? American Journal of Medical Genetics. 40: 515-517. PMID 1836106  1
1991 Weber B, Allen L, Magenis RE, Hayden MR. A low-copy repeat located in subtelomeric regions of 14 different human chromosomal termini Cytogenetics and Cell Genetics. 57: 179-183. PMID 1743071  1
1991 Weber B, Riess O, Hayden MR. A polymorphic DNA marker at the D10S106 locus Nucleic Acids Research. 19: 1725. PMID 1674143 DOI: 10.1093/nar/19.7.1725  1
1991 Hayden MR, Yuanhong M, Brunzell J, Henderson HE. Genetic variants affecting human lipoprotein and hepatic lipases Current Opinion in Lipidology. 2: 104-109.  1
1990 Devlin RH, Deeb S, Brunzell J, Hayden MR. Partial gene duplication involving exon-Alu interchange results in lipoprotein lipase deficiency American Journal of Human Genetics. 46: 112-119. PMID 2294743  1
1990 Bloch M, Hayden MR, Schömig-Spingler M. DNA testing for Huntington disease results in a modification of risk and not diagnosis of disease European Journal of Pediatrics. 149: 513. PMID 2140774 DOI: 10.1007/BF01959407  1
1990 Bloch M, Hayden MR. Opinion: Predictive testing for Hungtington disease in childhood: Challenges and implications American Journal of Human Genetics. 46: 1-4. PMID 2136787  1
1990 Kastelein JJP, Haines JL, Hayden MR. The gene causing familial hypoalphalipoproteinemia is not caused by a defect in the apo AI-CIII-AIV gene cluster in a Spanish family Human Genetics. 84: 396-400. PMID 1969839 DOI: 10.1007/BF00195807  1
1990 Hayden MR. Genetics, hyperlipidemia and atherosclerosis: An update Current Opinion in Lipidology. 1: 437-441.  1
1989 Lowry RB, Wood BJ, Cox TA, Hayden MR. Epiphyseal dysplasia, microcephaly, nystagmus, and retinitis pigmentosa American Journal of Medical Genetics. 33: 341-345. PMID 2801768  1
1989 Gilchrist DM, Hayden MR. Marfan's syndrome Cmaj : Canadian Medical Association Journal = Journal De L"Association Medicale Canadienne. 141: 656-657. PMID 2790594  1
1989 Hayden MR. The genetic aspects of atherosclerosis and hyperlipidemia Cmaj. 141: 135. PMID 2743228  1
1989 Quarrell OWJ, Bloch M, Hayden MR. Insurance and the Presymptomatic Diagnosis of Delayed-Onset Disease Jama: the Journal of the American Medical Association. 262: 2384-2385. PMID 2619811 DOI: 10.1001/jama.1989.03430170044017  1
1989 Theilmann JL, Robbins CA, Hayden MR. Methylation at the D4S95 locus and predictive testing American Journal of Human Genetics. 45: 477-479. PMID 2528290  1
1989 Fahy M, Robbins C, Bloch M, Turnell RW, Hayden MR. Different options for prenatal testing for Huntington's disease using DNA probes Journal of Medical Genetics. 26: 353-357. PMID 2525622  1
1989 Bloch M, Fahy M, Fox S, Hayden MR. Predictive testing for Huntington disease: II. Demographic characteristics, life-style patterns, attitudes, and psychosocial assessments of the first fifty-one test candidates American Journal of Medical Genetics. 32: 217-224. PMID 2522735  1
1989 Fox S, Bloch M, Fahy M, Hayden MR. Predictive testing for Huntington disease: I. Description of a pilot project in British Columbia American Journal of Medical Genetics. 32: 211-216. PMID 2522734  1
1988 Langlois S, Kastelein JJP, Hayden MR. Characterization of six partial deletions in the low-density-lipoprotein (LDL) receptor gene causing familial hypercholesterolemia (FH) American Journal of Human Genetics. 43: 60-68. PMID 2837085  1
1987 Hayden MR, Bloch M, Fox S, Crauford D. Ethical issues in preclinical testing in Huntington disease: response to Margery Shaw's invited editorial comment American Journal of Medical Genetics - Seminars in Medical Genetics. 28: 761-763. PMID 2962495  1
1987 Martin WRW, Hayden MR. Cerebral glucose and dopa metabolism in movement disorders Canadian Journal of Neurological Sciences. 14: 448-451. PMID 2960430  1
1987 Bloch M, Hayden MR. Preclinical testing in Huntington disease American Journal of Medical Genetics - Seminars in Medical Genetics. 27: 733-734. PMID 2957915  1
1987 Hayden MR, Hewitt J, Martin WRW. Studies in persons at risk for Huntington's disease New England Journal of Medicine. 317: 382-384. PMID 2955223  1
1987 Hayden MR, Hewitt J, Maresca A, Langlois S. A polymorphic DNA probe located to human chromosome 4p16 (D4S62) Nucleic Acids Research. 15: 3938. PMID 2884639 DOI: 10.1093/nar/15.9.3938  1
1986 Clark CM, Hayden MR, Stoessl AJ, Martin WRW. Regression model for predicting dissociations of regional cerebral glucose metabolism in individuals at risk for Huntington's disease Journal of Cerebral Blood Flow and Metabolism. 6: 756-762. PMID 2947906  1
1986 Bird TD, Hewitt J, Conneally PM, Hayden MR. Linkage of the G8 marker on chromosome 4 to Huntington's disease in a large American black family. The New England Journal of Medicine. 315: 1165-6. PMID 2945112 DOI: 10.1056/NEJM198610303151815  1
1986 Froster-Iskenius UG, Hayden MR, Kalousek DK. A family with Huntington disease and reciprocal translocation 4;5 American Journal of Human Genetics. 38: 759-767. PMID 2940859  1
1985 Wilson RD, Hayden MR. Bilateral renal agenesis in twins American Journal of Medical Genetics - Seminars in Medical Genetics. 21: 147-152, 167. PMID 3890542  1
1985 Hayden MR, Soles JA, Ward RH. Age of onset in siblings of persons with juvenile Huntington disease. Clinical Genetics. 28: 100-5. PMID 2931216  1
1985 Wilson RD, Hayden MR. Brief clinical report: bilateral renal agenesis in twins American Journal of Medical Genetics. 21: 147-152.  1
1983 Hayden MR. Reflections on the history of Huntington's chorea Trends in Neurosciences. 6: 122-124. DOI: 10.1016/0166-2236(83)90062-0  1
1982 Hayden MR, Beighton P. Genetic aspects of Huntington's chorea: Results of a national survey American Journal of Medical Genetics. 11: 135-141. PMID 6461251  1
1982 Hayden MR, MacGregor JM, Saffer DS, Beighton PH. The high frequency of juvenile Huntington's chorea in South Africa Journal of Medical Genetics. 19: 94-97. PMID 6210776  1
1981 Hayden MR, Berkowicz AL, Beighton PH, Yiptong C. Huntington's chorea on the island of Mauritius South African Medical Journal. 60: 1001-1002. PMID 6460324  1
1980 Hayden MR, Ehrlich R, Parker H, Ferera SJ. Social perspectives in Huntington's chorea South African Medical Journal. 58: 201-203. PMID 6447366  1
1980 Hayden MR, Hopkins HC, Macrae M, Beighton PH. The origin of Huntington's chorea in the Afrikaner population of South Africa South African Medical Journal. 58: 197-200. PMID 6447365  1
1980 Hayden MR, MacGregor JM, Beighton PH. The prevalence of Huntington's chorea in South Africa South African Medical Journal. 58: 193-196. PMID 6447364  1
1978 Hayden MR, Nelson MM. The fetal alcohol syndrome South African Medical Journal. 54: 571-574. PMID 569911  1
1977 Hayden MR, Beighton P. Huntington's chorea in the Cape Coloured community of South Africa South African Medical Journal. 52: 886-888. PMID 146919  1
1977 Hayden MR, Paul M, Vinik AI, Beighton P. IMPAIRED PROLACTIN RELEASE IN HUNTINGTON'S CHOREA. EVIDENCE FOR DOPAMINERGIC EXCESS The Lancet. 310: 423-426. PMID 70642 DOI: 10.1016/S0140-6736(77)90608-0  1
Show low-probability matches.